NCT06917079 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06917079
Title	BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Indications	lung non-small cell carcinoma Advanced Solid Tumor colorectal cancer pancreatic ductal adenocarcinoma
Therapies	BBO-11818 + Pembrolizumab BBO-11818 + Cisplatin + Pembrolizumab + Pemetrexed Disodium BBO-11818 + Carboplatin + Pembrolizumab + Pemetrexed Disodium BBO-11818 + Cetuximab BBO-11818
Age Groups:	adult \| senior
Covered Countries	USA

NCT06917079
Clinical Trial Detail